Design, sythesis and evaluation of a series of 3- or 4-alkoxy substituted phenoxy derivatives as PPARs agonists
Metrics: PDF 578 views | HTML 965 views | ?
Jun Zhang1, Xue-Jiao Wang1, Xin Liu1, Yi Huan2, Miao-Miao Yang2, Zhu-Fang Shen2, Wen-Qing Jia1, Zhi Jing1, Shu-Qing Wang1, Wei-Ren Xu3, Xian-Chao Cheng1, Run-Ling Wang1
1Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China
2Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
3Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China
Xian-Chao Cheng, email: firstname.lastname@example.org
Run-Ling Wang, email: email@example.com
Keywords: PPARs, Type 2 diabetes mellitus, bioisosterism, docking analysis, molecular dynamic simulations
Received: December 28, 2016 Accepted: January 25, 2017 Published: February 08, 2017
Peroxisome proliferators-activated receptors (PPARα, γ and δ) are potentially effective targets for Type 2 diabetes mellitus therapy. The severe effects of known glitazones and the successfully approved agents (saroglitazar and lobeglitazone) motivated us to study novelly potent PPARs drugs with improved safety profile. In this work, we received 15 carboxylic acids based on the combination principle to integrate the polar head of bezafibrate with the hydrophobic tail of pioglitazone. Another 12 tetrazoles based on the bioisosterism principle were obtained accordingly. Furthermore, in vitro PPARs transactivation assays on these 3- or 4-alkoxy substituted phenoxy derivatives afforded six compounds. Interactions and binding stability from the docking analysis and 20 ns molecular dynamic simulations confirmed the representative compounds to be suitable and plausible for PPARs pockets. The above-mentioned results demonstrated that the compounds may be used as reference for further optimization for enhanced PPARs activities and wide safety range.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.